Introduction
Woogene B&G Vaccine Research Institute was established in 2012 and has secured specialized technology through steady development of animal vaccines.
Woogene B&G’s vaccine R&D center has live attenuated vaccine and inactivated vaccine development technology, Inactivated vaccines (killed vaccines) development technology by ghost vector system, and cross-protection vaccine development technology by cell surface display system. In addition, Woogene B&G develops live attenuated vaccines capable of DIVA to meet the disease environment and consumer needs, as well as bacterial/viral complex and multivalent vaccines. We have the technology for pharmaceutical protein production on large scale, immunoassay techniques, genome sequencing by Baculovirus expression system. Furthermore, we have secured the expression of recombinant protein and purification, protein characteristics and therapeutic efficacy analysis technology.
Currently, more than 50% of the vaccine R&D center staffs have Ph.D degrees with relevant majors and composed of experts with more than 10 years of experience. Based on these, we are undertaking all research and development (R&D) for vaccine commercialization and national research projects are being carried out in cooperation with universities.
-
Cell culture technology
Primary cell culturing technology
Establishment of cell banking and cell preservation system for cell culturing
Cell library construction such as Vero, MDBK, MCBK, PK-15, MA104, MARC145, etc.
Single cell cloning technology
Adaptation technology to serum free/suspension cell
-
Analysis technology for disease causative agents of various livestock species
Characterization of viral disease causative agent
Characterization of bacteria disease causative agent
Pure isolation of disease-causing agents and in vitro culture technology
Virus titer analysis technology: TCID50, FAID50, PLA assay, real time PCR, etc.
Database construction of cytopathic effects between various cells and viruses
-
Mass culture technology
Development of a mass culture system for disease causative agents
Culture and mass culture of oocyte disease causative agents
Optimization of mass culture using roller bottles
Introduction of mass culture technology using microcarrier beads
Cell-free mass culture technology
-
Vaccine development technology
Development of live attenuated and inactivated vaccines
Development of dead cell vaccine using ghost vector system
Development of vaccine for simultaneous defense using cell surface expression system
Development of bacterial/viral combination vaccine and polynalent vaccine
-
Vaccine formulation technology
Development of freeze-drying protection agent for live vaccine
Development of immune booster for dead cell vaccine
Development of oral vaccine formulation
-
Protein medicine purification and analysis technology
Virus and Recombinant Protein Purification
Analysis of protein properties and therapeutic efficacy
-
Protein medicine mass production technology
Development of mass culture process using baculovirus expression system
Development of refining process for mass production
Purified protein purity and yield analysis
-
Immunoassay technology
Neutralization test
ELISA assay
Monoclonal/Polyclonal antibody assay
Immune gene expression analysis
-
Genetic analysis technology
Polymerase chain reaction
Real time polymerase chain reaction
Sequencing analysis
Phylogenetic analysis & Genetic homogeneity analysis